U.K.'s Direct To Pharmacy Model: Competition Risks

Law360, New York (February 25, 2008, 12:00 AM EST) -- In Autumn 2006, Pfizer announced that it intended from the following Spring to sell prescription medicines in the U.K. direct to pharmacies. This would be a fundamental departure from the traditional model of selling drugs to distributors who then re-sell to pharmacies as principals.

Under the new structure, known as “Direct to Pharmacy” or DTP, an existing distributor, Alliance, would act as “Logistic Service Provider” or LSP, with the contractual sale being made by Pfizer direct to the pharmacy.

Initially, it was intended that Pfizer appoint...
To view the full article, register now.